47576
5-氟脲嘧啶
≥99.0% (HPLC)
别名:
2,4-二羟基-5-氟嘧啶, 5-FU, 5-氟-2,4(1H,3H)-嘧啶二酮
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C4H3FN2O2
化学文摘社编号:
分子量:
130.08
EC Number:
200-085-6
UNSPSC Code:
12171500
PubChem Substance ID:
Beilstein/REAXYS Number:
127172
MDL number:
InChI key
GHASVSINZRGABV-UHFFFAOYSA-N
InChI
1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
SMILES string
FC1=CNC(=O)NC1=O
assay
≥99.0% (HPLC)
solubility
H2O: 10 mg/mL, clear
正在寻找类似产品? 访问 产品对比指南
Other Notes
Potent antineoplastic agent. Its determination in tissue with microbore HPLC and fluorescence detection; Metabolised to fluoro-2′-deoxyuridine monophosphate which inhibits DNA synthesis by blocking thymidylate synthetase
法规信息
新产品
此项目有
Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
C M Liang et al.
Molecular pharmacology, 21(1), 224-230 (1982-01-01)
C Jochheim et al.
Analytical biochemistry, 217(2), 285-291 (1994-03-01)
For the determination of the cytotoxic drug 5-fluorouracil in tissue, a sensitive and selective assay has been developed based on microbore high-performance liquid chromatography and fluorescence detection after pre-column derivatization with 4-bromomethyl-7-methoxycoumarin. 5-Chlorouracil was found to be an appropriate internal
Julia K J Ahlskog et al.
Bioorganic & medicinal chemistry letters, 19(16), 4851-4856 (2009-07-21)
We describe the synthesis and characterization of two acetazolamide derivatives containing either a charged fluorophore or an albumin-binding moiety, which restrict binding to carbonic anhydrase IX and XII present on tumor cells. In vivo studies showed the preferentially targeting of
Yuko Fujiwara et al.
EBioMedicine, 33, 33-48 (2018-07-28)
Activation of intrinsic p53 tumor-suppressor (TS) pathways is an important principle underlying cancer chemotherapy. It is necessary to elucidate the precise regulatory mechanisms of these networks to create new treatment strategies. Comprehensive analyses were carried out by microarray. Expression of
Jean-Yves Douillard et al.
The New England journal of medicine, 369(11), 1023-1034 (2013-09-13)
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. In this prospective-retrospective analysis, we
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持